Neurocrine/$NBIX
1D1W1MYTD1Y5YMAX
Capital at risk
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Ticker
- $NBIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.neurocrine.com
Neurocrine Metrics
BasicAdvanced
$14B
20.36
$6.82
0.38
-
Price and volume
Market cap
$14B
Beta
0.38
52-week high
$186.12
52-week low
$122.14
Average daily volume
1.2M
Financial strength
Current ratio
1.872
Quick ratio
1.46
Long term debt to equity
0.109
Total debt to equity
0.109
Interest coverage (TTM)
298.62%
Profitability
EBITDA (TTM)
904.5
Gross margin (TTM)
64.63%
Net profit margin (TTM)
20.91%
Operating margin (TTM)
25.67%
Effective tax rate (TTM)
24.96%
Revenue per employee (TTM)
$1,350,000
Management effectiveness
Return on assets (TTM)
11.70%
Return on equity (TTM)
22.09%
Valuation
Price to earnings (TTM)
20.363
Price to revenue (TTM)
4.128
Price to book
3.8
Price to tangible book (TTM)
14.51
Price to free cash flow (TTM)
16.003
Free cash flow yield (TTM)
6.25%
Free cash flow per share (TTM)
8.682
Growth
Revenue change (TTM)
34.42%
Earnings per share change (TTM)
101.21%
3-year revenue growth (CAGR)
26.34%
10-year revenue growth (CAGR)
71.87%
3-year earnings per share growth (CAGR)
57.74%
10-year earnings per share growth (CAGR)
16.93%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Analyst projections of the future price of Neurocrine stock.
Bulls say / Bears say
Current commercial momentum is strong. Q2 revenue rose 39% year on year to $959 million, INGREZZA sales rose 15% to $716 million, and management raised 2026 INGREZZA guidance to $2.825 billion-$2.875 billion. (PR Newswire)
Growth is broadening beyond INGREZZA. CRENESSITY generated $184 million in Q2, had reached about 15% of the estimated diagnosed CAH population, and VYKAT XR recorded $94 million of pro-forma quarterly sales after the Soleno acquisition. (PR Newswire)
Neurocrine has several potential future catalysts rather than relying only on marketed medicines. It remains on track for Phase III readouts for osavampator in major depressive disorder and direclidine in schizophrenia in the second half of 2027, while a new obesity triple-agonist programme has entered Phase I. (PR Newswire, PR Newswire)
INGREZZA faces a clear pricing headwind: management expects higher statutory rebates and additional concessions in 2027 and 2028, followed by a 2029 Medicare negotiated price that could imply a 25% to 34% discount. Management has said INGREZZA revenue is expected to decline when that maximum fair price takes effect. (MarketBeat, EarningsCalls.dev)
The portfolio is still concentrated in INGREZZA. It generated $716 million of Neurocrine’s $959 million Q2 revenue, while VYKAT XR contributed only $54 million because it was recognised from the 18 May acquisition date. (PR Newswire)
The Soleno acquisition creates execution and capital-allocation risk before VYKAT XR is fully established. The latest filing records $2.36 billion of cash paid net of cash acquired, a $52.2 million Soleno net loss from completion to quarter-end, and $104.7 million of acquisition-related and purchase-accounting costs. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neurocrine News
AllArticlesVideos
Funds containing Neurocrine
AllUSDEURGBP
Fund name | Fund size | $NBIX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.04% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.04% |
iShares Healthcare Innovation£DRDR | £1B | 1.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.94% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.94% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.